L
Leman Biotech
Pioneering low-dose CAR T immunotherapy to enhance tumor treatment efficacy
About Leman Biotech
LemanBio is a biotechnology startup based in Shenzhen, China, with its roots in Switzerland. The company operates in the biomedical industry, specializing in the development of innovative immunotherapy treatments for cancer. Their flagship product is the Le Mang bio repair booster CD19 CAR T injection, which has shown promising results in clinical research. This treatment uses the body's own immune system to fight cancer, a method known as immunotherapy.
The company's primary clients are healthcare providers and patients seeking advanced cancer treatments. LemanBio operates in the global biomedical market, with a focus on the Chinese and Swiss markets. The company's business model revolves around research and development of new treatments, clinical trials, and ultimately, the commercialization of successful therapies.
LemanBio's revenue is generated through the sale of their treatments to healthcare providers. The company also attracts investment from those interested in innovative biotech solutions. One of the unique aspects of LemanBio is its commitment to integrating artificial intelligence into its research and development process, aiming to create the next generation of physical tumor CAR T treatments.
In summary, LemanBio is a promising player in the biomedical industry, leveraging cutting-edge technology to develop innovative cancer treatments. Its focus on immunotherapy and the integration of AI sets it apart in a competitive market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Shenzhen, China
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 55.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Spinout, DT and LS, science-based, Swiss DT Biotech
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Mar 2026 | $28M | $110M | XtalPi · Fuho Capital · Zhongda Venture Capital | ↗ |
| GRANTOther financing | Mar 2025 | $23K | — | Founderful Campus | — |
Growth signals
Latest recorded traffic for Leman Biotech is 1.1K monthly website visits, up 450% over the last three months. Leman Biotech's team grew 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Tiantu Capital
XtalPi- YIYunfan Technology Investment
- FCFuho Capital
Founderful Campus
Series A1 investor entered at this stage
- ZCZhongda Venture Capital
Other known investors1 additional known investor
EPFL Swiss Federal Polytechnic School of Lausanne
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Leman Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Leman Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.